抗抑郁药文拉法辛的药代动力学研究进展

Advance in search for pharmacokinetics of an antipressant: venlafaxine

文拉法辛是已在中国上市的抗抑郁药,为第1个5-羟色胺和去甲肾上腺素再摄取双重抑制剂(SNRIs),由于其疗效肯定、起效快、副作用小、耐受性好,而备受关注。本文主要就文拉法辛在人体内的吸收、分布、代谢、排泄的药物动力学特征和给药方案、年龄、性别、肝肾功能损害等因素对这些过程的影响及与其他药物的相互作用做一综述。

Venlafaxine is an antidepressant that has marked in China, it is the first inhibitor that inhibits the ruptake of both serotonin and norepinephrine （SNRIs）. Because of positive clinical efficacy , immediate antipressant effect, less adverse reaction and better tolerability, it is getting obtained more and more attention. This article reviews the pharmacokinetics characters of venlafaxine, the effects of dosage regimens, age, gender, hepatic dysfunction and renal dysfuntion on its pharmacokinetics, and the drug- drug interactions.